Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
27.11.2019 14:00:00 EET | Business Wire | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.
“We look forward to sharing progress on our lead drug candidate for the treatment of KCNQ2 epileptic encephalopathy as we advance the understanding of ion channel activators and the important role they play in epilepsy and other neurological conditions with high unmet need,” said Michael Bozik, M.D., Chief Executive Officer of Knopp Biosciences.
Ion channels are proteins that regulate the excitability of cells, and drugs that modulate ion channels play an important role in treating a variety of neurological and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in nerve cells, targeting a devastating genetic mutation associated with neonatal encephalopathy, as well as other rare epilepsies and neuropathic pain.
Details related to Knopp Biosciences’ AES abstracts and poster presentations can be found in the table below.
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with AES Annual Meeting news and updates using the hashtag #AES2019.
|
Abstract Title |
Abstract Number / Presentation Details |
|
Discovery and Characterization of KB-3061: A Potent Kv7.2/7.3 Ion Channel Activator for the Treatment of KCNQ2-Neonatal Epileptic Encephalopathy |
Abstract 3.045: Poster Presentation
|
|
KB-3061 is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
|
Abstract 3.047: Poster Presentation
|
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is in Phase 2 clinical trials for severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.
Knopp's Kv7 research is supported under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191127005157/en/
Contact information
Media inquiries:
Kate Coyle
kate.coyle@icrinc.com
203-682-8210
Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Komainu Completes Two-Way Digital Asset Transfers for First Abu Dhabi Bank as Institutional Custody Framework Goes Live3.11.2026 11:30:00 EET | Press release
Komainu, a regulated digital asset services provider and custodian backed by Laser Digital and Blockstream, has completed the two-way transfer of a portfolio of digital assets with First Abu Dhabi Bank (FAB) through the institutional digital asset custody framework the two firms have established. The transfers settled instantly. The milestone marks the operationalisation of Komainu’s collaboration with FAB Global Markets, integrating regulated digital asset custody and connectivity capabilities with FAB’s existing infrastructure. The transfers demonstrate the bank’s ability to move digital assets both into and out of the custody environment, validating the infrastructure required to support institutional digital asset activity. The framework has also been designed to support future institutional financing solutions, including lending backed by digital assets held in regulated custody. This provides a foundation for FAB to further integrate digital assets into its financial markets infr
Klarna Expands Partnership With Mollie, Bringing Enhanced Dispute Management and Consumer FX to Merchants Across Europe3.11.2026 11:00:00 EET | Press release
Klarna, the everyday finance network, announced today an expanded agreement with Mollie, one of Europe’s leading payment service providers. Building on their existing partnership, the new contract brings additional Klarna capabilities, including enhanced dispute management and consumer FX, to Mollie’s more than 350,000 merchants. The new features will roll out across all Mollie’s integrations, via direct API, hosted payment page and via their extensive Platform partner plug in ecosystem. Merchants already offering Klarna through Mollie will gain access to these features through their existing integration. Merchants new to Klarna can offer Pay in Full, Pay in 3 interest-free installments and Financing at checkout, and can enable it within minutes. With Mollie’s recent acquisition of GoCardless and coverage across all EEA markets, the expanded agreement extends Klarna’s reach and product offering across the region. “This deepened agreement with Mollie opens up Klarna to merchants across
Bizzmine Unveils More Than 40 Quality, EHS and Compliance Solutions Alongside Major Advances in AI and User Experience3.11.2026 10:47:00 EET | Press release
Bizzmine has announced a major expansion of its intelligent QHSE platform at Digital Summit 2026. The company presented more than 40 ready to use solutions spanning Quality, Environment, Health and Safety (EHS) and Compliance, together with advances in artificial intelligence and a fundamentally renewed user experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102147396/en/ Bizzmine summit panel discussion The latest developments give organisations a broader range of operational processes to manage in one environment, with connected information, common governance and a clear view of responsibilities and completed work across locations. “What impresses me most is how quickly we can now turn innovation into value for our customers,” said Mark Abbas, CEO of Bizzmine. “In just one year, we have expanded from around 15 solutions to more than 40, got recognized by leading industry analysts for our EHS capabilities, introd
Hightouch Launches Match Booster in Europe, Raising Match Rates Without Compromising Compliance3.11.2026 10:02:00 EET | Press release
Hightouch, the leading agentic marketing platform, today launched Match Booster in the UK, Germany, France, Spain, and Italy. Match Booster helps brands, agencies, media networks, and publishers reach more of their customers on more than 50 ad platforms, including Google, Meta, Amazon, TikTok, and The Trade Desk, by adding to their consented first-party data instead of replacing it. Until now, European advertisers have had two options. They could send first-party data to ad platforms alone and accept the match rates they got. Or they could hand it to a traditional onboarding provider that swaps it for a proprietary ID and drops any customer its graph can’t find, sometimes leaving audiences smaller than they started. Global companies also end up running separate US and EU workflows to meet data residency rules. “Better match rates shouldn’t depend on where your customers live,” said Matthew Lubeck, General Manager, EMEA at Hightouch. “European companies have been told that more reach me
Building on Netherlands NextGen Momentum, Trilliant Showcases Why the Next Generation of AMI is Being Defined by Choice at Enlit Europe 20263.11.2026 10:00:00 EET | Press release
Trilliant, a technology platform partner enabling utilities to gain real-time visibility and optimize performance across an increasingly dynamic energy landscape, will showcase its Power of Choice approach at Enlit Europe 2026, taking place 10–12 November in Vienna, Austria. The company will highlight how intelligent software and device-independent technologies help utilities modernize infrastructure and prepare for evolving grid demands. Trilliant’s participation at Enlit Europe follows its recent selection by Dutch distribution system operators to support the Netherlands’ NextGen smart metering programme. Trilliant’s role includes developing and delivering gateways supported by its transformed UnitySuite® platform, which will be demonstrated during the conference. At Enlit Europe, Trilliant will spotlight its Power of Choice approach, enabling utilities to integrate multiple vendors and technologies without proprietary lock-in while building a foundation for next-generation AMI and g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom